Goldman Sachs details trading with ‘Ming’
High Court hears evidence from Goldman director Duncan Rutherford in market manipulation case against Mark Warminger.
Trading in Fisher & Paykel Healthcare was the focus of evidence given at the High Court on the fourth day of hearings in a lawsuit against fund manager Mark Warminger.
The Financial Markets Authority is alleging market manipulation by Mr Warminger, who managed more than $600 million for Milford
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Tim Hunter
Thu, 29 Sep 2016
Thu, 29 Sep 2016
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Goldman Sachs details trading with ‘Ming’
62005